Table 2.

National Wilms Tumor Study (NWTS) patient characteristics by end stage renal disease (ESRD) type

Patient characteristic		ESRD-PBWT		ESRD-CRF		All ESRD
		No	%	No	%	No	%
Gender
	Male	28	50.9	54	45.8	82	47.4
	Female	27	49.1	64	54.2	91	52.6
Ethnicity
White, non-Hispanic		37	67.3	80	67.8	117	67.6
	African	11	20.0	16	13.6	27	15.6
	Hispanic	6	10.9	16	13.6	22	12.7
	Other	1	1.8	6	5.1	7	4.0
Age at ESRD (years)
	0–4	33	50.0	32	27.1	65	37.6
	5–9	16	29.1	11	9.3	27	15.6
	10–14	3	5.5	16	13.6	19	11.0
	15–19	2	3.6	17	14.4	19	11.0
	20–24	1	1.8	26	22.0	27	15.6
	25+	0	0.0	16	13.6	16	9.2
Congenital syndrome
	DDS	1	1.8	28	23.7	29	16.8
	WAGR	1	1.8	14	11.9	15	8.8
	GU	6	10.9	13	11.0	19	11.0
	None	47	85.5	63	53.4	110	63.6
Onset of ESRD
Before WT diagnosis		0	0.0	8	6.8	8	4.6
During WT treatment		27	49.1	16	13.6	43	30.9
During remission		28	50.9	94	79.7	122	70.5
Laterality of WT
	Unilateral	0	0.0	89	75.4	89	51.4
Synchronous bilateral		37	67.3	26	22.0	63	36.4
Metachronous bilateral		18	32.7	3	2.5	21	12.1
Initial ESRD treatment
	Peritoneal dialysis	24	42.9	41	34.7	65	37.6
	Hemodialysis	28	51.8	56	47.5	84	48.6
	Dialysis (unspecified)	3	5.4	3	2.5	6	3.7
	Preemptive Transplant	0	0.0	18	15.2	18	10.4
Cause of death
	WT/Rx	23	41.8	7	5.9	30	17.3
	ESRD	7	12.7	19	16.1	26	15.0
	Other	3	5.5	4	3.4	7	4.0
	Still living	22	40.0	88	74.5	110	63.6

PBWT progressive bilateral Wilms tumor; CRF chronic renal failure; DDS Denys-Drash syndrome; WAGR Wilms tumor, aniridia, genitourinary anomalies, retardation; WT Wilms tumor; GU genitourinary